Erlotinib u nemocných s nemalobuněčným karcinomem plic (NSCLC) účinný u všech podskupin nemocných i v České republice

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Title in English	Erlotinib in patients with non-small cell lung cancer (NSCLC): Efficacy in all subgroups of patients even in the Czech Republic
Authors	SKŘIČKOVÁ Jana PEŠEK M. ZATLOUKAL P.
Year of publication	2010
Type	Article in Proceedings
Conference	Edukační sborník
MU Faculty or unit	Faculty of Medicine
Citation
Field	Pneumology
Keywords	Erlotinib; NSCLC; Czech Republic
Description	A multi-centre study confirms efficacy of Erlotinib in treatment of NSCLC in all subgroups of patients with non-small cell lung cancer (NSCLC). Efficacy in all patient subgroups was confirmed even in the Czech Republic
Related projects:	Environment - carcinogenesis - oncology